期刊文献+

高渗三黄液治疗难治性溃疡的疗效观察 被引量:3

Observation of Hypertonic Sanhuang Decoction on Refractory Ulcer
下载PDF
导出
摘要 目的探讨高渗三黄液对临床难治性溃疡的有效性和安全性。方法采用随机、对照的研究方法,将219例难治性溃疡患者随机分为治疗组(自拟高渗三黄液治疗)和对照组(传统外科换药治疗)。连续用药2周,分别于给药后1周和2周进行临床治愈率及有效率的比较。结果两组患者临床综合疗效比较:给药后1周及给药后2周,两者总有效率比较,差异有统计学意义(P<0.05),治疗组疗效明显高于对照组。两组患者均未见严重不良反应。结论高渗三黄液组治疗难治性溃疡明显优于传统换药治疗。 Objective:To evaluate the effect and the safety of Hypertonic Sanhuang Decoction on clinical refractory ulcer treatment.Methods:By using the method of randomized and controlled,219 cases of refractory ulcer were randomly divided into the treatment group with the Hypertonic Sanhuang Decoction and the control group with the conventional surgicaldressing treatment for 2 weeks.Respectively after administration of 1 weeks and 2 weeks,there were some indicators compared such as the clinical cure rate and more efficient.Results:Comparison of two groups of patients with clinical comprehensive therapeutic effect,the clinical effective rates in the treatement group were higher significantly than those in the treatment group.There were no serious adverse reactions in 2 groups.Conclusion:The effect of the Hypertonic Sanhuang Decoction is superior to that of the traditional dressing treatment.
出处 《中国中医急症》 2013年第10期1701-1702,共2页 Journal of Emergency in Traditional Chinese Medicine
基金 河北省廊坊市科技支撑计划项目(2011013099)
关键词 难治性溃疡 高渗 三黄液 安全性 Refractory ulcer Hypertonic Sanhuang Decoction Safety
  • 相关文献

参考文献4

二级参考文献19

  • 1牛轶雯,陆树良,青春,廖镇江,林源.糖基化细胞外基质对成纤维细胞生物学行为的影响[J].上海第二医科大学学报,2004,24(9):697-699. 被引量:14
  • 2邓家德,李杨,肖正华,凌艳英,冯泰宝.黄芪对糖尿病足溃疡处成纤维细胞增殖作用的研究[J].江西医学检验,2005,23(5):389-392. 被引量:9
  • 3邓家德,肖正华,凌艳英,冯泰宝.黄芪对糖尿病足溃疡处成纤维细胞合成Ⅰ、Ⅲ型胶原的影响[J].海南医学,2007,18(4):128-129. 被引量:7
  • 4Medina A, Scott PG, Ghahary A, et al. Pathophysiology of chronic non-healing wounds [ J]. J Bum Care Rehabil, 2005, 26: 306 -319.
  • 5Hehenberger K. , Heilborn JD, Brismar K, et al. Inhibited pro- liferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased forma- tion of l-lactate [J]. Wound Repair Regen, 1998, 6 (2) : 135-141.
  • 6Facchiano F, Lentini A, Fogliano V, et al. Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo [J]. Am J Pathol. 2002, 161 : 531 -41.
  • 7Niu Y, Xie T, Ge K, et al. Effects of extracellular matrix gly- cosylation on proliferation and apoptosis of human dermal fibroblasts via the receptor for advanced glycosylated end products [J]. Am J Dermatopatho, 12008, 30 (4): 344-351.
  • 8Lohwasser C, Neureiter D, Weigle B, et al. The receptor for advanced glycation end products is highly expressed in the skin andupregulated by advanced glycation end products and tumor necrosisfactor-alpha [J]. J Invest Dermato, 2006, 126 (2): 291-299.
  • 9竹原和彦.增殖因子の临床应用[A].见:宫園平编.細胞增殖因子の作用と疾患[M].东京:羊土社,1998.116-121.
  • 10涉谷正史.VEGF、ファミリ一とVEGFレヤプタ一[J].実験医,2000,18(5):546-546.

共引文献5

同被引文献34

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部